Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)

Phase 1

Completed

Conditions: Indeterminate Colitis
Inflammatory Bowel Diseases
Crohn Disease
Ulcerative Colitis

Interventions: Drug: Methylprednisolone

First Posted Date: 2022-10-20

Last Posted Date: 2024-11-26

Lead Sponsor: Stanford University

Target Recruit Count: 3

Registration Number: NCT05587673

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States

Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.

Early Phase 1

Conditions: Graves Ophthalmopathy

Interventions: Drug: Rapamycin
Drug: Methylprednisolone

First Posted Date: 2022-09-08

Last Posted Date: 2022-09-08

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 140

Registration Number: NCT05532072

Locations: 🇨🇳
First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shaanxi, China

Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction

Phase 2

Active, not recruiting

Conditions: ST Elevation Myocardial Infarction
Inflammatory Response
Myocardial Reperfusion Injury
Myocardial Injury

Interventions: Drug: Methylprednisolone
Drug: Isotonic saline

First Posted Date: 2022-07-18

Last Posted Date: 2023-10-19

Lead Sponsor: Thomas Engstrom

Target Recruit Count: 530

Registration Number: NCT05462730

Locations: 🇩🇰
Heart Center, Rigshospitalet, Copenhagen, Capital Region, Denmark

Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients

Phase 3

Completed

Conditions: COVID-19 Respiratory Infection
FLU
Cold; Influenza
Bacterial Pneumonia
COVID-19 Pneumonia

Interventions: Dietary Supplement: Kunamin®
Drug: Favipiravir
Drug: Enoxaparin
Drug: Lansoprazole
Drug: Paracetamol
Drug: Ceftriaxone/ Clarithromycin
Drug: Methylprednisolone

First Posted Date: 2022-06-14

Last Posted Date: 2022-06-14

Lead Sponsor: RAAS Nutritionals, LLC

Target Recruit Count: 71

Registration Number: NCT05417997

Locations: 🇹🇷
Kayseri City Hospital, Kayseri, Kayseri Province, Turkey

Multi-Modal Anesthesia Protocol in Pain Management of Patients Undergoing Posterior Lumbar Spinal Fusion Surgery

Phase 4

Completed

Conditions: Pain Management
Posterior Spinal Fusion

Interventions: Drug: Morphine
Drug: Toradol
Drug: Orphenadrine
Drug: Gabapentin
Drug: Acetaminophen
Drug: Bupivacaine
Drug: Epinephrine
Drug: Xylocaine Injectable Solution
Drug: Methylprednisolone

First Posted Date: 2022-06-10

Last Posted Date: 2022-06-10

Lead Sponsor: University of Puerto Rico

Target Recruit Count: 100

Registration Number: NCT05413902

Locations: 🇵🇷
Puerto Rico Medical Center - University District Hospital, San Juan, Puerto Rico

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Phase 3

Active, not recruiting

Conditions: Plasma Cell Myeloma Recurrent

Interventions: Drug: Isatuximab SC
Drug: Isatuximab IV
Drug: Dexamethasone
Drug: Pomalidomide
Drug: Montelukast
Drug: Paracetamol / Acetaminophen
Drug: Diphenhydramine
Drug: Methylprednisolone

First Posted Date: 2022-06-06

Last Posted Date: 2024-11-14

Lead Sponsor: Sanofi

Target Recruit Count: 531

Registration Number: NCT05405166

Locations: 🇺🇸
Arizona Oncology Associates, PC - HAL- Site Number : 8400015, Prescott Valley, Arizona, United States
🇺🇸
Rocky Mountain Cancer Centers, LLP- Site Number : 8400021, Aurora, Colorado, United States
🇺🇸
Mayo Clinic- Site Number : 8400008, Jacksonville, Florida, United States

and more 143 locations